Literature DB >> 8895247

Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils.

Nadia M J Rupniak1, Emma Carlson, Susan Boyce, Janine K Webb, Raymond G Hill.   

Abstract

Intravenous administration of the NK1 receptor antagonist L-733,060 to gerbils 3 h before intraplantar injection of formalin caused a dose-dependent and complete inhibition of the late, but not early, phase nociceptive response (paw licking). The ID50 for L-733,060 (0.17 mg/kg) revealed a greater than 50-fold separation in potency over its less active enantiomer L-733,061 (ID50 > or = 10 mg/kg). In contrast, the non-brain penetrant quaternary ketone NK1 receptor antagonist, L-743,310 (3 mg/kg), did not attenuate the response to formalin, indicating that the antinociceptive effect of blockade of NK1 receptors by L-733,060 in this assay is centrally-mediated. These findings add to the preclinical evidence that NK1 receptor antagonists may be of therapeutic use as centrally-acting analgesics.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895247     DOI: 10.1016/0304-3959(96)03109-0

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  18 in total

1.  Role of tachykinin NK receptors on the local and remote injuries following ischaemia and reperfusion of the superior mesenteric artery in the rat.

Authors:  Danielle G Souza; Vanessa A Mendonça; Maria Salete de A Castro; Steve Poole; Mauro M Teixeira
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene.

Authors:  A Zimmer; A M Zimmer; J Baffi; T Usdin; K Reynolds; M König; M Palkovits; E Mezey
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

Review 3.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 4.  Migraine and the trigeminovascular system-40 years and counting.

Authors:  Messoud Ashina; Jakob Møller Hansen; Thien Phu Do; Agustin Melo-Carrillo; Rami Burstein; Michael A Moskowitz
Journal:  Lancet Neurol       Date:  2019-05-31       Impact factor: 44.182

Review 5.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

6.  Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Authors:  Dane D Jensen; TinaMarie Lieu; Michelle L Halls; Nicholas A Veldhuis; Wendy L Imlach; Quynh N Mai; Daniel P Poole; Tim Quach; Luigi Aurelio; Joshua Conner; Carmen Klein Herenbrink; Nicholas Barlow; Jamie S Simpson; Martin J Scanlon; Bimbil Graham; Adam McCluskey; Phillip J Robinson; Virginie Escriou; Romina Nassini; Serena Materazzi; Pierangelo Geppetti; Gareth A Hicks; Macdonald J Christie; Christopher J H Porter; Meritxell Canals; Nigel W Bunnett
Journal:  Sci Transl Med       Date:  2017-05-31       Impact factor: 17.956

7.  The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

Authors:  Miguel Muñoz; Marisa Rosso
Journal:  Invest New Drugs       Date:  2009-01-17       Impact factor: 3.850

8.  Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells.

Authors:  Xuqi Li; Guodong Ma; Qingyong Ma; Wei Li; Jiangbo Liu; Liang Han; Wanxing Duan; Qinhong Xu; Han Liu; Zheng Wang; Qing Sun; Fengfei Wang; Erxi Wu
Journal:  Mol Cancer Res       Date:  2013-01-23       Impact factor: 5.852

9.  TRPV1-mediated protection against endotoxin-induced hypotension and mortality in rats.

Authors:  Youping Wang; Martin Novotny; Veronika Quaiserová-Mocko; Greg M Swain; Donna H Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-03-12       Impact factor: 3.619

10.  NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.

Authors:  Miguel Muñoz; Marisa Rosso; Francisco J Aguilar; Miguel A González-Moles; Maximino Redondo; Francisco Esteban
Journal:  Invest New Drugs       Date:  2007-09-29       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.